SCHEDULE: Rosalind Advisors Divests Entire OptiNose Stake

Rosalind Advisors, Inc. and related entities have reported a complete divestment of their beneficial ownership in OptiNose, Inc., now holding 0% of common shares.

Summary

• Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven A.J. Salamon, and Gil Aharon are the reporting persons.
• The filing is an Amendment No. 8 to a Schedule 13G for OptiNose, Inc. common shares.
• As of the event date, the reporting persons collectively hold 0.00 shares, representing 0.0% of the class.
• The beneficial ownership includes 0.00 shares with sole voting power, 0.00 shares with shared voting power, 0.00 shares with sole dispositive power, and 0.00 shares with shared dispositive power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of OptiNose, Inc.

Sentiment

Score: 5

Explanation: The filing is a factual report of a change in beneficial ownership, specifically a divestment, and does not contain information that inherently indicates a positive or negative outlook for the company's operations or financial performance.

Future Outlook

No forward-looking statements or guidance are provided in this beneficial ownership filing.

Industry Context

This filing is a routine regulatory update regarding a change in beneficial ownership by an institutional investor. It does not provide insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: A previous significant holder has exited their position, which may be noted by other investors.

Key Dates

Recommendation

This Schedule 13G Amendment No. 8 reports that Rosalind Advisors, Inc. and related entities no longer hold a beneficial ownership stake in OptiNose, Inc., with their reported ownership at 0%. This filing is a routine regulatory update on a change in ownership and does not contain financial performance data, strategic updates, or forward-looking guidance that would warrant a change in investment thesis. Investors should consider this information in the context of OptiNose's broader financial health and market position, but this specific filing does not provide a basis for a strong buy or sell recommendation.

Keywords

OptiNose, Rosalind Advisors, SEC filing, Schedule 13G, beneficial ownership, divestment, common shares